New stock news | Bangshun Pharmaceutical's Hong Kong IPO prospectus has expired

Hangzhou Bangshun Pharmaceutical Co., Ltd. (hereinafter referred to as Bangshun Pharmaceutical) submitted its Hong Kong stock prospectus on January 22, 2026, which expired after 6 months on July 22, 2026. China Securities Co., Ltd. International was its exclusive sponsor. The prospectus shows that Bangshun Pharmaceutical is a biotechnology company focusing on the fields of oncology and autoimmune diseases. The company has established a pipeline including a new drug application (NDA) stage candidate drug (bezitexetanib), a registration-stage clinical candidate drug (CX1440), and five preclinical stage candidate drugs (CX03, CX12, CX13, CX15, and CX16).